NOT KNOWN DETAILS ABOUT HEMGENIX

Quantity of eligible patients: CDEC mentioned the uncertainty in the quantity of sufferers with moderately intense to critical hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical experts consulted by CADTH indicated that some sufferers who're classified as obtaining gentle or moderate sickness could have a intense bleeding phenot